211 related articles for article (PubMed ID: 25907661)
1. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.
Jousma E; Rizvi TA; Wu J; Janhofer D; Dombi E; Dunn RS; Kim MO; Masters AR; Jones DR; Cripe TP; Ratner N
Pediatr Blood Cancer; 2015 Oct; 62(10):1709-16. PubMed ID: 25907661
[TBL] [Abstract][Full Text] [Related]
2. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
3. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
[TBL] [Abstract][Full Text] [Related]
4. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
5. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.
Dodd RD; Mito JK; Eward WC; Chitalia R; Sachdeva M; Ma Y; Barretina J; Dodd L; Kirsch DG
Mol Cancer Ther; 2013 Sep; 12(9):1906-17. PubMed ID: 23858101
[TBL] [Abstract][Full Text] [Related]
6. Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Sweeney EE; Burga RA; Li C; Zhu Y; Fernandes R
Sci Rep; 2016 Nov; 6():37035. PubMed ID: 27833160
[TBL] [Abstract][Full Text] [Related]
7. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
[TBL] [Abstract][Full Text] [Related]
8. Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse.
Summers MA; Vasiljevski ER; Mikulec K; Peacock L; Little DG; Schindeler A
Mol Genet Metab; 2018 Apr; 123(4):518-525. PubMed ID: 29477258
[TBL] [Abstract][Full Text] [Related]
9. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
10. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
11. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Wu J; Dombi E; Jousma E; Scott Dunn R; Lindquist D; Schnell BM; Kim MO; Kim A; Widemann BC; Cripe TP; Ratner N
Pediatr Blood Cancer; 2012 Feb; 58(2):173-80. PubMed ID: 21319287
[TBL] [Abstract][Full Text] [Related]
12. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.
Cirone P; Andresen CJ; Eswaraka JR; Lappin PB; Bagi CM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):525-38. PubMed ID: 24442130
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.
Ferguson MJ; Rhodes SD; Jiang L; Li X; Yuan J; Yang X; Zhang S; Vakili ST; Territo P; Hutchins G; Yang FC; Ingram DA; Clapp DW; Chen S
Pediatr Blood Cancer; 2016 Feb; 63(2):206-13. PubMed ID: 26375012
[TBL] [Abstract][Full Text] [Related]
15. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.
Prada CE; Jousma E; Rizvi TA; Wu J; Dunn RS; Mayes DA; Cancelas JA; Dombi E; Kim MO; West BL; Bollag G; Ratner N
Acta Neuropathol; 2013 Jan; 125(1):159-68. PubMed ID: 23099891
[TBL] [Abstract][Full Text] [Related]
16. Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.
Fischer-Huchzermeyer S; Chikobava L; Stahn V; Zangarini M; Berry P; Veal GJ; Senner V; Mautner VF; Harder A
BMC Res Notes; 2018 Jul; 11(1):520. PubMed ID: 30055648
[TBL] [Abstract][Full Text] [Related]
17. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Chang T; Krisman K; Theobald EH; Xu J; Akutagawa J; Lauchle JO; Kogan S; Braun BS; Shannon K
J Clin Invest; 2013 Jan; 123(1):335-9. PubMed ID: 23221337
[TBL] [Abstract][Full Text] [Related]
18. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Gross AM; Dombi E; Widemann BC
Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
[TBL] [Abstract][Full Text] [Related]
19. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K
Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491
[TBL] [Abstract][Full Text] [Related]
20. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
Yang FC; Chen S; Clegg T; Li X; Morgan T; Estwick SA; Yuan J; Khalaf W; Burgin S; Travers J; Parada LF; Ingram DA; Clapp DW
Hum Mol Genet; 2006 Aug; 15(16):2421-37. PubMed ID: 16835260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
